A new review in Genes & Diseases highlights how colorectal cancer rewires its use of nutrients to support growth, evade immune defenses and withstand treatment. By connecting these metabolic changes with tumor behavior, the article outlines potential routes toward earlier detection and more personalized therapies.
The review, prepared by a team from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and Ganzhou Cancer Hospital, Gannan Medical University, examines how altered glucose, lipid and amino acid metabolism shapes colorectal cancer. Its central message is that metabolism does more than supply energy: it helps determine how tumors survive, spread and respond to medicines.
One prominent feature is the Warburg effect, in which cancer cells convert glucose into lactate even when oxygen is available. This process supports the production of materials needed for growth. However, colorectal tumors retain metabolic flexibility, with some cells also drawing on mitochondrial energy production. That adaptability can help explain why blocking a single metabolic pathway may produce different outcomes across tumors.
Lactate emerges as an important player. Beyond being a metabolic byproduct, it can serve as fuel and influence the environment surrounding a tumor. Changes in lactate production and transport are linked to chemotherapy resistance and immune suppression, making these processes potential targets for treatment combinations.
The article also describes how altered fat metabolism and dependence on amino acids, including glutamine, can sustain cancer cells. These pathways interact with cancer-driving signals and the machinery controlling cell survival. Exploiting such dependencies could create opportunities to weaken tumors or restore sensitivity to medicines.
Metabolic changes extend beyond cancer cells. Immune cells and supporting cells compete for nutrients and exchange metabolites within the tumor microenvironment. These interactions can undermine immune responses and help cancer establish itself in distant organs, including the liver. Understanding this cooperation may reveal ways to interrupt metastatic growth.
The review points toward metabolic biomarkers as possible tools for improving early diagnosis and matching treatments to tumor characteristics. It also highlights the potential of combining metabolic interventions with chemotherapy, targeted medicines or immunotherapy.
Uncertainties remain. Metabolic requirements vary between tumor types, disease stages and cellular populations, and many proposed approaches still require clinical validation. Particular gaps concern cancer stem cells and microsatellite-stable colorectal cancer, which represents most cases.